IP Library Patent Application 10585763
Patent Application
App. No. 10/585,763

Differentiation of Cd34 Positive Cell to Megakaryocyte and Multiplication

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/585,763
Abstract

An object of the present invention is to provide a method for more efficiently differentiating CD34 + cells derived from umbilical cord blood into megakaryocytic lineage cells and for generating platelets. Coculture of CD34 + cells derived from umbilical cord blood with immortalized stromal cells in the presence of cytokines has enabled cell proliferation up to the 100,000-fold level, which has been impossible to achieve to date.

Claims (8)

1 . A method for preparing a megakaryocytic lineage cell, which comprises coculturing a CD34 + cell with an immortalized stromal cell.

2 . The method according to claim 1 , wherein a CD34 + cell and an immortalized stromal cell are cocultured in the presence of a cytokine.

3 . The method according to claim 1 , which comprises: the step (1 st step) of coculturing a CD34 + cell with an immortalized stromal cell in the presence of a cytokine; and the step (2 nd step) of culturing the resultant cell after removal of the immortalized stromal cell in the presence of a cytokine.

4 . The method according to claim 1 , which comprises: the step (1 st step) of cocultuirng a CD34 + cell with an immortalized stromal cell in the presence of a cytokine, so as to prepare a megakaryocytic lineage progenitor cell that is a hematopoietic progenitor cell capable of differentiating into a megakaryocytic lineage cell; and the step (2 nd step) of culturing the megakaryocytic lineage progenitor cell in the presence of a cytokine after removal of the immortalized stromal cell.

5 . The method according to claim 3 or 4 , wherein the cytokine used in the 1 st step is an SCF, TPO, or Flt-3/Flk-2 ligand.

6 . The method according to claim 3 or 4 , the cytokine(s) used in the 2 nd step is/are (1) TPO, (2) TPO and IL3, (3) TPO, IL1, IL3, IL6 and IL11, or (4) TPO, IL1, IL3, IL6, IL11, SCF, and FL.

7 . The method according to any one of claims 1 to 6 , wherein a CD34 + cell separated from umbilical cord blood is used.

8 . A megakaryocytic lineage cell, which is prepared by the method according to any one of claims 1 to 7 .

Assignments (2)
CHANGE OF NAME Recorded Jul 24, 2009
From: LABORATOIRES SERONO S.A.
To: MERCK SERONO SA
Reel/Frame 023000/0862 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2006
From: MATSUNAGA, TAKUYA; HAMADA, HIROFUMI; NIITSU, YOSHIRO
To: RENOMEDIX INSTITUTE INC.
Reel/Frame 018111/0730 →